Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

MRNA stock could be at full value here if analysts' projections for lower sales in 2023 come to pass, despite a potential rebound by Q4 2023. The post Analysts See a Dip and Then a Rebound In Moderna's Future appeared first on InvestorPlace.

Analysts See a Dip and Then a Rebound In Moderna's Future

Is it time to buy this once high-flying stock?

3 Reasons Moderna Stock Is a Bargain Right Now

Maybe -- but not because of today's news.

Moderna Rose Today -- Is It a Buy?

The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.

Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod

Why you might need to get an omicron-specific Covid vaccine booster shot, even though you never got one for delta, according to Moderna's chief medical officer.

Why you may need an omicron-specific vaccine even after this Covid surge ends, Moderna's top doctor says

Here's Why Moderna Is Rising Today

The stock price of Moderna Inc (NASDAQ: MRNA) increased by 6.18% in the previous trading session. This is why it happened.

Moderna (MRNA) Stock: Why The Price Went Up

Even as MRNA stock plumbs new depths, Moderna's commitment to combat Covid-19 variant strains offers hope of a turnaround. The post Value Seekers Ought To Have Moderna on Their Radar Now appeared first on InvestorPlace.

Value Seekers Ought To Have Moderna on Their Radar Now

Moderna Inc (NASDAQ: MRNA) is now in the “oversold” territory after a 65% hit to its stock price over the past six months, says Sanctuary Wealth's chief investment officer. Why Kilburg likes Moderna On CNBC's “Power Lunch”, Jeff Kilburg said he was interested in owning Moderna on sale as the company had promising prospects for […] The post Moderna receives full FDA approval: is it time to buy the stock?

Moderna receives full FDA approval: is it time to buy the stock?

The FDA granted full authorization to Moderna's COVID-19 vaccine.

Why Moderna Stock Was Gaining Today

Moderna Inc (NASDAQ: MRNA) is trading higher Monday after the U.S. Food and Drug Administration approved the Biologics License Application for SPIKEVAX to prevent COVID-19 in individuals 18 years of age and older. SPIKEVAX, the company's mRNA Covid-19 vaccine, has now received approval from regulators in more than 70 countries.

Why Moderna Shares Are Rising Today

The company is the second vaccine maker to get full FDA approval for a COVID-19 vaccine.

Moderna's COVID vaccine wins full FDA approval

Moderna said Monday that U.S. health regulators from the Food and Drug Administration have granted full approval to the company's COVID-19 vaccine.

Moderna COVID-19 vaccine receives full FDA approval

The FDA has given complete approval to Moderna Inc's  MRNA COVID-19 vaccine, dubbed Spikevax, to prevent COVID-19 in individuals 18 years of age and older. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Moderna's COVID-19 Vaccine Becomes Second To Score Complete FDA Approval

Shares of Moderna Inc. MRNA, +2.56% gained 3.4% in trading on Monday after the company said it received full approval from the Food and Drug Administration for its COVID-19 vaccine, which is now called Spikevax. The FDA has granted full approval to one other COVID-19 shot: BioNTech SE BNTX, +3.36% and Pfizer Inc.'s PFE, -3.34% Comirnaty.

FDA grants full approval to Moderna's COVID-19 vaccine

Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel 807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries CAMBRIDGE, MA / ACCESSWIRE / January 31, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older. "Our COVID-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from COVID-19 infection, hospitalization and death.

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax

Advanced Micro Devices

Chevron

D.R. Horton

General Motors

Western Digital

Jim Cramer is one of the most controversial stock market pundits, and one of the most widely followed. He hosts the "Mad Money" segment on CNBC television, and founded TheStreet.com, a popular financial website.

Catching Falling Knives: Jim Cramer's Picks, and My Own

Transocean

Tesla

A handful of analysts and investment banks see these popular stocks plummeting this year.

3 Stocks That Can Plunge 42% to 92% in 2022, According to Wall Street

BioNTech SE

Pfizer

Are Prospects of a 4th Dose of the Pfizer-BioNTech Vaccine Dwindling?

Caesars Entertainment

Domino's Pizza

Etsy

Netflix

NVIDIA

Some of the pandemic's hottest stocks are among the worst performers so far in 2022.

Here Are The Biggest Losing Stocks In The Market's Worst Month Since March 2020

The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific B-cell responses and guide toward broadly neutralizing antibody (bnAbs) development.

IAVI, Moderna Kickstart HIV Vaccine Antigens Trial Delivered Through mRNA Technology

Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.

Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab

Moderna Inc. announced Wednesday that it had begun its first study of an omicron-specific booster dose of its COVID-19 vaccine.

Moderna begins study for omicron-specific booster shot

Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development.

IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology

It's part of a bigger conversation about the need for variant-specific COVID shots.

News for Moderna Stock (MRNA)